Latest & greatest articles for heparin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heparin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heparin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heparin

21. General medicine: Edoxaban is non-inferior to low-molecular-weight heparin for treating cancer-associated venous thromboembolism

General medicine: Edoxaban is non-inferior to low-molecular-weight heparin for treating cancer-associated venous thromboembolism Edoxaban is non-inferior to low-molecular-weight heparin for treating cancer-associated venous thromboembolism | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Edoxaban is non-inferior to low-molecular-weight heparin for treating cancer-associated venous thromboembolism Article Text Commentary General medicine

2018 Evidence-Based Medicine

23. Outcomes following the use of nebulized heparin for inhalation injury (HIHI Study) Full Text available with Trip Pro

Outcomes following the use of nebulized heparin for inhalation injury (HIHI Study) 29456608 2018 11 13 1751-1437 19 1 2018 Feb Journal of the Intensive Care Society J Intensive Care Soc Outcomes following the use of nebulized heparin for inhalation injury (HIHI Study). 80-82 10.1177/1751143717737408 eng Journal Article Review 2017 11 28 England J Intensive Care Soc 101538668 1751-1437 2018 2 20 6 0 2018 2 20 6 0 2018 2 20 6 1 ppublish 29456608 10.1177/1751143717737408 10.1177_1751143717737408

2017 Journal of the Intensive Care Society

24. Acetylsalicylic Acid versus Low-Molecular-Weight Heparin for Venous Thromboembolism Prophylaxis: Comparative Clinical Effectiveness and Guidelines

Acetylsalicylic Acid versus Low-Molecular-Weight Heparin for Venous Thromboembolism Prophylaxis: Comparative Clinical Effectiveness and Guidelines Acetylsalicylic Acid versus Low-Molecular-Weight Heparin for Venous Thromboembolism Prophylaxis: Comparative Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Acetylsalicylic Acid versus Low-Molecular-Weight Heparin for Venous Thromboembolism Prophylaxis: Comparative Clinical Effectiveness and Guidelines Acetylsalicylic (...) Acid versus Low-Molecular-Weight Heparin for Venous Thromboembolism Prophylaxis: Comparative Clinical Effectiveness and Guidelines Published on: November 14, 2017 Project Number: RC0941-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of acetylsalicylic acid versus low-molecular-weight heparin for venous thromboembolism prophylaxis in patients undergoing total hip or knee replacement? What

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

25. Heparin Lock Solutions for Open-Ended Vascular Access Devices: An Update Regarding the Clinical Effectiveness, Safety, and Guidelines

Heparin Lock Solutions for Open-Ended Vascular Access Devices: An Update Regarding the Clinical Effectiveness, Safety, and Guidelines Heparin Lock Solutions for Open-Ended Vascular Access Devices: An Update Regarding the Clinical Effectiveness, Safety, and Guidelines | CADTH.ca Find the information you need Heparin Lock Solutions for Open-Ended Vascular Access Devices: An Update Regarding the Clinical Effectiveness, Safety, and Guidelines Heparin Lock Solutions for Open-Ended Vascular Access (...) Devices: An Update Regarding the Clinical Effectiveness, Safety, and Guidelines Published on: September 13, 2017 Project Number: RA0929-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question What is the clinical effectiveness of heparin lock solutions to maintain the patency of open-ended central vascular access devices? What are the evidence-based guidelines associated with the use of heparin lock solutions to maintain the patency of open-ended central vascular

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

26. Heparin (5,000 u/0.5 mL) for Catheter Lock or Flush: An Update Regarding the Clinical Effectiveness, Safety, and Guidelines

Heparin (5,000 u/0.5 mL) for Catheter Lock or Flush: An Update Regarding the Clinical Effectiveness, Safety, and Guidelines Heparin (5,000 u/0.5 mL) for Catheter Lock or Flush: An Update Regarding the Clinical Effectiveness, Safety, and Guidelines | CADTH.ca Find the information you need Heparin (5,000 u/0.5 mL) for Catheter Lock or Flush: An Update Regarding the Clinical Effectiveness, Safety, and Guidelines Heparin (5,000 u/0.5 mL) for Catheter Lock or Flush: An Update Regarding the Clinical (...) Effectiveness, Safety, and Guidelines Published on: September 7, 2017 Project Number: RA0928-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question What is the clinical effectiveness and safety of heparin 5,000 u/0.5 mL for catheter lock or flush? What are the evidence-based guidelines associated with the use of heparin for catheter lock or flush? Key Message Two systematic reviews (both including meta-analyses) were identified regarding heparin (5,000 u/0.5 mL

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

27. Bivalirudin versus Heparin Monotherapy in Myocardial Infarction. Full Text available with Trip Pro

Bivalirudin versus Heparin Monotherapy in Myocardial Infarction. The comparative efficacy of various anticoagulation strategies has not been clearly established in patients with acute myocardial infarction who are undergoing percutaneous coronary intervention (PCI) according to current practice, which includes the use of radial-artery access for PCI and administration of potent P2Y12 inhibitors without the planned use of glycoprotein IIb/IIIa inhibitors.In this multicenter, randomized, registry (...) -based, open-label clinical trial, we enrolled patients with either ST-segment elevation myocardial infarction (STEMI) or non-STEMI (NSTEMI) who were undergoing PCI and receiving treatment with a potent P2Y12 inhibitor (ticagrelor, prasugrel, or cangrelor) without the planned use of glycoprotein IIb/IIIa inhibitors. The patients were randomly assigned to receive bivalirudin or heparin during PCI, which was performed predominantly with the use of radial-artery access. The primary end point

2017 NEJM Controlled trial quality: predicted high

28. Clinical effectiveness of a Bayesian algorithm for the diagnosis and management of heparin-induced thrombocytopenia Full Text available with Trip Pro

Clinical effectiveness of a Bayesian algorithm for the diagnosis and management of heparin-induced thrombocytopenia Essentials We previously published a diagnostic algorithm for heparin-induced thrombocytopenia (HIT). In this study, we validated the algorithm in an independent large healthcare system. The accuracy was 98%, sensitivity 82% and specificity 99%. The algorithm has potential to improve accuracy and efficiency in the diagnosis of HIT.Background Heparin-induced thrombocytopenia (HIT (...) ) is a life-threatening drug reaction caused by antiplatelet factor 4/heparin (anti-PF4/H) antibodies. Commercial tests to detect these antibodies have suboptimal operating characteristics. We previously developed a diagnostic algorithm for HIT that incorporated 'four Ts' (4Ts) scoring and a stratified interpretation of an anti-PF4/H enzyme-linked immunosorbent assay (ELISA) and yielded a discriminant accuracy of 0.97 (95% confidence interval [CI], 0.93-1.00). Objectives The purpose of this study

2017 EvidenceUpdates

29. Antiangiogenic effects of decorin restored by unfractionated, low molecular weight, and nonanticoagulant heparins Full Text available with Trip Pro

Antiangiogenic effects of decorin restored by unfractionated, low molecular weight, and nonanticoagulant heparins Pregnancies affected by preeclampsia (PE) or fetal growth restriction (FGR) display increases in thrombin generation and reductions in angiogenesis and cell growth. There is significant interest in the potential for low molecular weight heparins (LMWHs) to reduce the recurrence of PE and FGR. However, LMWH is associated with an increased risk of bleeding. Therefore, it is of vital (...) importance to determine the exact molecular function of heparins in pregnancy if they are used as therapy for pregnant women. We aimed to determine this using our model for PE/FGR in microvascular endothelial cells. The expression of decorin, a proteoglycan, was reduced to mimic PE/FGR in these cells compared with controls. Four concentrations of unfractionated heparin (UFH), LMWH, and nonanticoagulant heparin (NAC) were added to determine the effect on thrombin generation, angiogenesis, and cell growth

2017 Blood advances

30. Pharmacological Treatments for Type II Heparin-Induced Thrombocytopenia: Clinical Effectiveness

Pharmacological Treatments for Type II Heparin-Induced Thrombocytopenia: Clinical Effectiveness Pharmacological Treatments for Type II Heparin-Induced Thrombocytopenia: Clinical Effectiveness | CADTH.ca Find the information you need Pharmacological Treatments for Type II Heparin-Induced Thrombocytopenia: Clinical Effectiveness Pharmacological Treatments for Type II Heparin-Induced Thrombocytopenia: Clinical Effectiveness Published on: April 19, 2017 Project Number: RB1085-000 Product Line (...) : Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness the use of fondaparinux to treat patients with type II heparin-induced thrombocytopenia? What is the clinical effectiveness the use of direct oral anticoagulants to treat patients with type II heparin-induced thrombocytopenia? Key Message One systematic review and eight non-randomized studies were identified regarding the clinical effectiveness of fondaparinux and/or direct oral

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

31. Serologic characterization of anti-protamine/heparin and anti-PF4/heparin antibodies Full Text available with Trip Pro

Serologic characterization of anti-protamine/heparin and anti-PF4/heparin antibodies Anti-protamine (PRT)/heparin antibodies are a newly described class of heparin-dependent antibodies occurring in patients exposed to PRT and heparin during cardiac surgery. To understand the biologic significance of anti-PRT/heparin antibodies, we developed a murine monoclonal antibody (ADA) specific for PRT/heparin complexes and compared it to patient-derived anti-PRT/heparin antibodies, as well as comparing (...) polyclonal and monoclonal antibodies with anti-platelet factor 4 (PF4)/heparin. Using monoclonal antibodies and polyclonal patient-derived antibodies, we show distinctive binding patterns of anti-PRT/heparin antibodies as compared with PF4/heparin antibodies. Whereas heparin-induced thrombocytopenia (HIT) antibody binding to PF4/heparin is inhibited by relatively low doses of heparin (0-1 U/mL), anti-PRT/heparin antibodies, including ADA, retain binding to PRT/heparin over a broad range of heparin

2017 Blood advances

32. Economic Evaluation of Unfractionated Heparin Versus Low-Molecular-Weight Heparin to Prevent Venous Thromboembolism in General Medical and Non Orthopedic Surgical Patients

Economic Evaluation of Unfractionated Heparin Versus Low-Molecular-Weight Heparin to Prevent Venous Thromboembolism in General Medical and Non Orthopedic Surgical Patients Economic Evaluation of Unfractionated Heparin Versus Low-Molecular-Weight Heparin to Prevent Venous Thromboembolism in General Medical and Non Orthopedic Surgical Patients | CADTH.ca CADTH Document Viewer Economic Evaluation of Unfractionated Heparin Versus Low-Molecular-Weight Heparin to Prevent Venous Thromboembolism (...) in General Medical and Non Orthopedic Surgical Patients Table of Contents Search this document Economic Evaluation of Unfractionated Heparin Versus Low-Molecular-Weight Heparin to Prevent Venous Thromboembolism in General Medical and Non Orthopedic Surgical Patients April 2017 Key Finding: Economic Evaluation The price of low-molecular-weight heparin (LMWH) has decreased since it was marketed in the mid‑1990s in Canada, while unfractionated heparin (UFH) has recently become more costly because of changes

2017 CADTH - Plasma Products

33. Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke. Full Text available with Trip Pro

Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke. Low-molecular-weight heparins (LMWHs) and heparinoids are anticoagulants that may have more powerful antithrombotic effects than standard unfractionated heparin (UFH) but a lower risk of bleeding complications. This is an update of the original Cochrane Review of these agents, first published in 2001 and last updated in 2008.To determine whether antithrombotic therapy with LMWHs

2017 Cochrane

34. Prospective Study of Routine Heparin Avoidance Hemodialysis in a Tertiary Acute Care Inpatient Practice Full Text available with Trip Pro

Prospective Study of Routine Heparin Avoidance Hemodialysis in a Tertiary Acute Care Inpatient Practice Extracorporeal circuit (EC) anticoagulation with heparin is a key advance in hemodialysis (HD), but anticoagulation is problematic in inpatients at risk of bleeding. We prospectively evaluated a heparin-avoidance HD protocol, clotting of the EC circuit (CEC), impact on dialysis efficiency, and associated risk factors in our acute care inpatients who required HD (January 17, 2014 to May 31 (...) , 2015).HD sessions without routine EC heparin were performed using airless dialysis tubing. Patients received systemic anticoagulation therapy and/or antiplatelets for non-HD indications. We observed patients for indications of CEC (interrupted HD session, circuit loss, or inability to return blood). The primary outcome was CEC. Logistic regression with generalized estimating equations assessed associations between CEC and other variables.HD sessions (n = 1200) were performed in 338 patients (204

2017 Kidney international reports

35. Evaluating the safety and efficacy of regional citrate compared to systemic heparin as anticoagulation for continuous renal replacement therapy in critically ill patients: A service evaluation following a change in practice Full Text available with Trip Pro

Evaluating the safety and efficacy of regional citrate compared to systemic heparin as anticoagulation for continuous renal replacement therapy in critically ill patients: A service evaluation following a change in practice Following the implementation of citrate anticoagulation for continuous renal replacement therapy, we evaluate its first year of use and compare it to the previously used heparin, to assess whether our patients benefit from the recently reported advantages of citrate. We (...) retrospectively analysed 2 years of data to compare the safety and efficacy of citrate versus heparin. The results have shown that 43 patients received continuous renal replacement therapy with heparin, 37 patients with citrate. We found no significant difference in metabolic control of pH, urea and creatinine after 72 h. Filters anticoagulated with citrate had significantly longer median lifespan (33 h vs 17 h; p = 0.001), shorter downtime (0 h vs 5 h; p = 0.015) and less filter sets per patient day (0.37 vs

2017 Journal of the Intensive Care Society

36. One-Year Mortality for Bivalirudin vs Heparins Plus Optional Glycoprotein IIb/IIIa Inhibitor Treatment Started in the Ambulance for ST-Segment Elevation Myocardial Infarction: A Secondary Analysis of the EUROMAX Randomized Clinical Trial. Full Text available with Trip Pro

One-Year Mortality for Bivalirudin vs Heparins Plus Optional Glycoprotein IIb/IIIa Inhibitor Treatment Started in the Ambulance for ST-Segment Elevation Myocardial Infarction: A Secondary Analysis of the EUROMAX Randomized Clinical Trial. Uncertainty exists regarding potential survival benefits of bivalirudin compared with heparin with routine or optional use of glycoprotein IIb/IIIa inhibitors (GPIs) in patients with ST-segment elevation myocardial infarction (STEMI). Few data are available (...) regarding long-term mortality in the context of contemporary practice with frequent use of radial access and novel platelet adenosine diphosphate P2Y12 receptor inhibitors.To assess the effect of bivalirudin monotherapy compared with unfractionated or low-molecular-weight heparin plus optional GPIs on 1-year mortality.This international, randomized, open-label clinical trial (EUROMAX [European Ambulance Acute Coronary Syndrome Angiography]) included 2198 patients with STEMI undergoing transport

2017 JAMA cardiology Controlled trial quality: predicted high

37. Comparative effectiveness of bivalirudin versus heparin monotherapy for percutaneous coronaryintervention (PCI)

Comparative effectiveness of bivalirudin versus heparin monotherapy for percutaneous coronaryintervention (PCI) Comparative effectiveness of bivalirudin versus heparin monotherapy for percutaneous coronary intervention (PCI) Comparative effectiveness of bivalirudin versus heparin monotherapy for percutaneous coronary intervention (PCI) HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been (...) made for the HTA database. Citation HAYES, Inc.. Comparative effectiveness of bivalirudin versus heparin monotherapy for percutaneous coronary intervention (PCI) Lansdale: HAYES, Inc.. Directory Publication. 2016 Authors' objectives Anticoagulation is recommended for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). Two commonly employed options include heparin and bivalirudin. Heparin is an indirect thrombin inhibitor; it binds and activates

2017 Health Technology Assessment (HTA) Database.

38. Heparin Flushing of IV Lines

Heparin Flushing of IV Lines Rapid Review 1 Heparin flushing of IV lines Citation Centre for Clinical Effectiveness. 2017. Heparin flushing of IV lines: Rapid Review. Centre for Clinical Effectiveness, Monash Health, Melbourne, Australia. Executive Summary Background Monash Health are working on improving procedural and maintenance documentation as a result of the dramatic increase in the size of the lines service with the opening of the new Children’s Hospital. As part of this, they are re (...) - considering the use of heparin for flushing paediatric lines which is common practice around the world. Changing practice from heparin to saline at Monash Health would be a significant change in practice. Anaesthetics have engaged the Centre for Clinical Effectiveness to undertake a rapid review of current literature about the use of heparin for flushing paediatric lines. Objective The purpose of this Rapid Review was to synthesise recent evidence pertaining to the use of heparin versus saline flushing

2017 Monash Health Evidence Reviews

39. BEXSERO - Recombinant Neisseria meningitidis serogroup B Neisseria Heparin Binding Antigen fusion proteinRecombinant Neisseria meningitidis serogroup B Neisserial Adhesin A proteinRecombinant Neisseria meningitidis serogroup B factor H binding protein

BEXSERO - Recombinant Neisseria meningitidis serogroup B Neisseria Heparin Binding Antigen fusion proteinRecombinant Neisseria meningitidis serogroup B Neisserial Adhesin A proteinRecombinant Neisseria meningitidis serogroup B factor H binding protein Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact

2017 Health Canada - Drug and Health Product Register